Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) in Combination With Idarubicin in Relapsed or Refractory Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00331513
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:37.262712+00:00
Published At
2013-09-30T00:00:00+00:00
Record Updated At
2013-09-30
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Promyelocytic Leukemia (M3)", "Blastic Phase Chronic Myelogenous Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2013-09-30"
protocolSection.identificationModule.nctId
"NCT00331513"
protocolSection.identificationModule.officialTitle
"A Phase 1 Study of Suberoylanilide Hydroxamic Acid (Vorinostat, SAHA) in Combination With Idarubicin in Relapsed or Refractory Leukemia"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) (protocolSection.conditionsModule.conditions)
  • Adult Acute Promyelocytic Leukemia (M3) (protocolSection.conditionsModule.conditions)
  • Blastic Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (protocolSection.conditionsModule.conditions)
  • Previously Treated Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Relapsing Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
  • Secondary Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Secondary Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.